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JOURNAL WATCHCD47-Blocking Antibodies
and Atherosclerosis
John J. Ryan, MDP hagocytosis is a well understood processwhereby pathogens and cell debris areremoved from within the body, and it is an
important homeostatic mechanism in health and dis-
ease. What is less commonly discussed is the process
of “efferocytosis.” This term, derived from the Latin
preﬁx effero-, meaning “to take away, to carry to the
grave, or to bury” (1), is a more nuanced mechanism
of phagocytosis, which focuses on the clearance of
apoptotic cells by neutrophils and macrophages.
Efferocytosis has been studied in cancer and in a
more limited capacity in atherosclerosis. In a recent
study in Nature, Kojima et al. (2) described the role
of CD47 in the development of atherosclerosis and
proposed that anti-CD47 antibodies may represent a
novel therapeutic strategy for treating coronary
artery disease by promoting efferocytosis.
In this paper (2), CD47 was found to be increased in
the atherosclerotic regions of human coronary and
carotid arteries. Of note, the increase in CD47 was
localized to the necrotic core of the plaques and was
up-regulated to a greater extent in people with a
history of stroke or transient ischemic attack,
compared with samples from patients with stable
asymptomatic carotid lesions. On the basis of the
intriguing human and in vitro data, the authors
studied the role of CD47 in apolipoprotein E/ mice
treated with angiotensin II infusion—a small animal
model prone to the development of atherosclerosis.
When these animals were treated with inhibitory
antibodies directed against CD47, Kojima et al. (2)
found a marked reduction in atherosclerosis
compared with those treated with immunoglobulin G
control. In other models of chronic atherosclerosis,
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anti-CD47 antibodies had similar effects. The authors
also found that there was a marked decrease in re-
sidual apoptotic bodies in the atherosclerotic plaque
of animals treated with anti-CD47 antibodies,
consistent with impaired efferocytosis in atheroscle-
rosis. Additionally, colocalization studies and elec-
tron microscopy studies demonstrated that the
number of free apoptotic bodies (i.e., not associated
with an intraplaque macrophage) was decreased after
anti-CD47 antibody treatment, thereby implicating
failed efferocytosis in the pathogenesis of CD47-
mediated atherosclerosis. Furthermore, the athero-
sclerotic lesions in the animals treated with anti-CD47
antibodies had smaller necrotic cores and less
apoptotic debris.
In a series of mechanistic studies, Kojima et al. (2)
showed that CD47 interrupts efferocytosis by bind-
ing to the antiphagocytic receptor signal regulatory
protein (SIRP)-a (Figure 1). Activation of SIRPa typi-
cally results in phosphorylation of SHP1, thereby
blocking phagocytosis. The downstream effect of
anti-CD47 antibodies includes a decrease in phos-
phorylation of SHP1 inside the atherogenic
plaque, thereby reactivating efferocytosis. Using co-
expression studies and a bioinformatics approach,
the authors showed that CD47 was up-regulated by
tumor necrosis factor (TNF) acting on the type 1 TNF
receptor (TNFR1). TNF was already known to be
increased in atherosclerosis, and the ﬁndings by
Kojima et al. (2) suggest a potentially important
mechanism through which TNF may contribute to
the atheromatous plaque. Interestingly, vascular
smooth muscle cells treated with recombinant TNF
had increased CD47 levels and were less likely to beiversity of Utah, Salt Lake City, Utah. Dr. Ryan has
to disclose.
FIGURE 1 The Role of CD47 and TNF in the Development of Atherosclerosis
NFKB1 ¼ nuclear factor kappa-light-chain-enhancer of activated B cells subunit 1; SHP1 ¼ Src homology region 2 domain-containing
phosphatase-1; TNF ¼ tumor necrosis factor.
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414susceptible to phagocytosis by macrophages, even
when exposed to pro-apoptotic stimuli, such as
oxidized low-density lipoprotein or staurosporine.
Moreover, the effect on atherosclerosis and effer-
ocytosis was even more pronounced when anti-CD47
antibodies were administered in combination with
either etanercept or inﬂiximab.
TRANSLATIONAL PERSPECTIVE
The translational application of this work is poten-
tially very signiﬁcant. Within the ﬁeld of coronary
artery disease, no currently available therapeutic
agents are approved to speciﬁcally target the
immunological pathways involved in atheroscle-
rosis, although canakinumab (a human monoclonal
antibody targeted at interleukin-1 beta) and meth-
otrexate are currently being evaluated in clinical
trials in patients with atherosclerosis (NCT01327846
and NCT01594333, respectively). It is therefore
exciting that agents that target CD47 levels
might reduce the burden of coronary artery
disease. Enthusiasm must be tempered at this time,
because of the current absence of demonstrableclinical beneﬁt in the use of TNF antagonists,
namely inﬂiximab, adalimumab, and etanercept
(NCT01356758), in protecting against coronary artery
disease in psoriatic arthritis, although these studies
are ongoing. There are also several nonrandomized,
population-based studies as well as pre-clinical data
that propose a protective effect of immunomodula-
tory therapy. However, this form of therapy is not
currently incorporated into clinical guidelines as a
treatment option for atherosclerosis or ischemic
heart disease (3).
The link between increased CD47 expression
and decreased efferocytosis is important in cancer,
and has led to a phase I clinical trial using anti-CD47
in patients with relapsed acute myeloid leukemia
(NCT02678338). Moreover, there are additional
possibilities for utilizing anti-CD47 antibodies in
other disease processes where apoptosis is reduced
and cell proliferation is pronounced, such as pulmo-
nary arterial hypertension. Indeed, increased CD47
in pulmonary endothelial cells has already been
implicated in the pathogenesis of this occlusive
vasculopathy (4). CD47 has also been identiﬁed
as playing a causative role in systolic heart
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 5 , 2 0 1 6 Ryan
A U G U S T 2 0 1 6 : 4 1 3 – 5 CD47 in Atherosclerosis
415failure, possibly by altering excitation-contraction
coupling (5).
The ﬁndings of Kojima et al. (2) open up an exciting
avenue in vascular biology that may also lead to new
treatment options for treating atheromatous plaque,
which still remains an important clinical need.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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